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Abstract
Background: The pivotal role of mitochondria in energy production and free radical generation suggests that the
mitochondrial genome could have an important influence on the expression of multifactorial age related diseases.
Substitution of T to C at nucleotide position 16189 in the hypervariable D-loop of the control region (CR) of mitochondrial
DNA (mtDNA) has attracted research interest because of its suspected association with various multifactorial diseases. The
aim of the present study was to compare the frequency of this polymorphism in the CR of mtDNA in patients with coronary
artery disease (CAD, n=482) and type 2 diabetes mellitus (T2DM, n=505) from two study centers, with healthy individuals
(n=1481) of Middle European descent in Austria.
Methodology and Principal Findings: CR polymorphisms and the nine major European haplogroups were identified by
DNA sequencing and primer extension analysis, respectively. Frequencies and Odds Ratios for the association between
cases and controls were calculated. Compared to healthy controls, the prevalence of T16189C was significantly higher in
patients with CAD (11.8% vs 21.6%), as well as in patients with T2DM (11.8% vs 19.4%). The association of CAD, but not the
one of T2DM, with T16189C remained highly significant after correction for age, sex and body mass index (BMI) and was
independent of the two study centers.
Conclusions and Significance: Our results show for the first time a significant association of T16189C with CAD in a Middle
European population. As reported in other studies, in patients with T2DM an association with T16189C in individuals of
European decent remains questionable.
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Introduction
Mitochondria produce energy to sustain cell growth and function,
but they also generate harmful free radicals and mediate apoptosis.
Mutations of mitochondrial DNA (mtDNA) can cause diseases such as
MELAS (mitochondrial encephalomyopathy, lactic acidosis and
stroke-like episodes) and Leber’s hereditary optic neuropathy. In rare
cases of type 2 diabetes mellitus (T2DM), pathogenic mtDNA
mutations have been linked to the disease. The most frequent mtDNA
mutation found to be associated with enhanced risk of diabetes is
A3234G, which affects the tRNA
Leu gene. When present in a high
percentage (.85%) of genomes, the mutation often leads to MELAS.
When A3234G is present at lower heteroplasmy (5% to 30%), the
mutation is associated with maternally inherited diabetes mellitus and
deafness (MIDD), accounting for 0.2–2% of diabetes cases [1,2].
In addition, there is evidence that ‘‘neutral’’ polymorphisms in
mtDNA may actually be risk factors for age related multifactorial
diseases and can influence disease outcome. The T to C
substitution at position 16189 within the regulatory displacement
loop (D-loop) of mtDNA is such a polymorphism, with reports of
associations with a variety of multifactorial disorders [3–13]. This
substitution (referred to in the literature as the ‘‘16189 variant’’)
frequently produces an uninterrupted polycytosine (poly-C) tract
in the D-loop. Because polynucleotide tracts are susceptible to
replication errors, heteroplasmic (more than one distinct popula-
tion of mtDNAs in the same individual) length variation of such
uninterrupted poly-C tracts is frequently observed [11,14].
Associations of the 16189 variant have been found for metabolic
syndrome [9], dilated cardiomyopathy [11], left ventricular
hypertrophy [12], lacunar cerebral infarction [13], hereditary
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index, and high placental-to-birth weight ratio as well as thinness
in young adults [16–18]. The 16189 variant was also reported to
be associated with higher fasting insulin and glucose levels, insulin
resistance, and/or T2DM in Europe [3,19,20] and Asia [4–9,21].
However, other studies failed to find significant associations
between the 16189 variant and T2DM or metabolic phenotypes in
the United Kingdom [14,22] and Finland [23].
Recently, an association of T16189C to coronary artery disease
(CAD) was reported in Arabs of Saudi descent [10].
Mitochondria are likely to be important for insulin secretion in
pancreatic b cells. In the ATP-sensitive K
+ channel (KATP)-
dependent pathway of insulin secretion, oxidative phosphorylation
in mitochondria leads to ATP production and consequently to a
rise in the ATP:ADP ratio. This event directs closure of the KATP,
resulting in depolarisation of the plasma membrane, opening of
voltage-gated Ca
2+ channels, and finally to exocytosis and insulin
secretion [24]. Mitochondrial generation of ATP may be linked to
glucose sensing through interaction with b cell glucokinase.
Therefore, mtDNA mutations (or reduced mtDNA content) that
result in lower levels of ATP production may influence both
insulin secretion and glucose sensing, thus contributing to insulin
resistance [25]. Lower mtDNA copy number in peripheral blood
mononuclear cells was shown to precede the development of
diabetes [26].
It has been demonstrated that enhanced production of reactive
oxygen species (ROS), which are generated predominantly in
mitochondria, is a common feature of risk factors for atheroscle-
rosis. ROS are central to some of the most important processes
implicated in atherogenesis, including dysfunction and apoptosis of
endothelial cells, activation of matrix metalloproteinases, growth
of vascular smooth muscle cells and their migration into the
intimal layer, expression of adhesion molecules, and oxidation of
low density lipoproteins [27,28]. Hence, mtDNA mutations that
alter the production of ROS might contribute to the generation of
CAD.
The aim of the present study was to compare the frequency of
T16189C as well as other polymorphisms in the control region
(CR) of mtDNA from patients with T2DM and CAD versus
healthy controls in Middle Europe.
Results
Clinical characteristics of the patients and controls are shown in
Table 1.
Because there are several studies reporting contradictory
findings as to the association of the 16189 variant and T2DM,
we first analyzed the frequency of T16189C in our patient and
control groups. We found an elevated frequency of T16189C in
patients with T2DM compared to healthy controls (Table 2). In
patients with CAD we also found an elevated frequency of
T16189C compared to healthy controls (Table 2).
We next analyzed the frequency of the poly-C tract. A poly-C
tract is generated when the wild type tyrosine in position 16189 of
the mtDNA is substituted by a cytosine (T16189C) resulting in a
polynucleotide tract of at least 10 cytosines (Figure 1B). Frequent-
ly, the poly-C tract also leads to a heteroplasmic length variation,
causing varying lengths of the poly-C tract (.10 cytosines) in
different mtDNA molecules of one subject (Figure 1B). However,
the T16189C polymorphism can be accompanied by a second
mutation for example at position 16192, interrupting the poly-C
tract (Figure 1C). In this manuscript, the term poly-C tract was
used for CR sequences with the T16189C polymorphism and an
uninterrupted poly-C tract of at least 10 cytosine residues. For
instance, the CR sequence illustrated in Figure 1C was regarded as
T16189C, but not as a poly-C tract, whereas the sequence
illustrated in Figure 1B was taken into account in both groups. The
frequency of the poly-C tract was significantly higher in patients
with CAD and T2DM compared to the control population
(Table 2).
When patients with diabetes were excluded from the CAD
cohort (n=358), there was an even greater difference in the
frequency of T16189C and the poly-C tract between the CAD and
the control group [T16189C: 22.1% vs. 11.8%, p,0.000001, OR
2.11 (1.6–2.8); poly-C tract: 16.2% vs. 9.1%, p,0.0001, OR 1.93
(1.4–2.7)].
Using multiple regression analysis, the association between
T16189C and the poly-C tract and CAD remained significant
after correction for age, sex and BMI (T16189C: p,0.00005;
poly-C tract: p,0.05; Table 2). Because of the substantial age
difference of patients with CAD and controls, we stratified the
Table 1. Characteristics of the study populations.
Controls CAD
a T2DM
b
Graz Salzburg Graz Salzburg
n=1481 n=191 n=291 n=226 n=279
Mean (SD
c) age (years) 51.5 (6.1) 53.7 (5.5) 69.8 (9.4) 73.1 (11.0) 62.3 (11.6)
Male (%) 64.3 90.6 68.0 40.7 57.0
Mean (SD
c) BMI
d (kg/m
2) 26.7 (4.1) 27.0 (3.2)
(189)
27.4 (4.0) 27.6 (5.0) 30.1 (5.5)
History of myocardial infarction (%) 0 62.8 41.2 12.4 n.a.
e
Diagnosis of diabetes (%) 0 12.0 34.7 100 100
Hypertension (%) 13.8
(1372)
49.2 79.0 73.0 54.9
aCAD = coronary artery disease.
bT2DM = type 2 diabetes mellitus.
cSD = standard deviation.
dBMI = body mass index.
en.a. = not available.
Missing values represent less than 10% of the total, with the exception of BMI data in patients with T2DM from Graz and hypertension data in patients with T2DM from
Salzburg.
doi:10.1371/journal.pone.0016455.t001
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Odds Ratios and 95% Confidence Intervals.
Controls CAD
a
P-Valuec
(Pearson chi-
square test)
ORd
(95% CIe)
aORf
(95% CIe) T2DM
b
P-Valuec
(Pearson chi-
square test)
ORd
(95% CIe)
aORf
(95% CIe)
n=1481 n=482 n=505
T16189C 11.8 21.6 ,0.0000001 2.05 (1.6–2.7) 2.17 (1.5–3.1)*** 19.4 ,0.00005 1.80 (1.4–2.4) 1.46 (1.0–2.2)
Poly-C tract 9.1 15.8 ,0.00005 1.87 (1.4–2.5) 1.61 (1.1–2.5)* 15.4 ,0.0001 1.82 (1.4–2.5) 1.45 (0.9–2.3)
aCAD = coronary artery disease.
bT2DM = type 2 diabetes mellitus.
cP-value: compared to controls.
dOR = Odds Ratio.
eCI = Confidence Interval.
fadjusted for age, sex and body mass index.
*p,0.05, p.0.01.
***p,0.001.
doi:10.1371/journal.pone.0016455.t002
Figure 1. MtDNA CR sequence variations around position 16189. A) Wild-type sequence. B) T16189C polymorphism, causing a poly-C tract
with heteroplasmic length variation. C) T16189C polymorphism with an additional polymorphism at position 16192, interrupting the poly-C tract.
doi:10.1371/journal.pone.0016455.g001
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individuals from the control group (age $57 years, n=322). When
the frequencies of T16189C and the poly-C tract in patients with
CAD were compared to this control group (mean age 60 years)
with a similar mean of age as the patients with CAD (mean age 63
years), the difference of the frequencies remained significant
[T16189C: 21.6% vs. 12.7%, p,0.005, OR 1.89 (1.3–2.8); poly-C
tract: 15.8% vs. 9.3%, p,0.01, OR 1.82 (1.2–2.9)].
Moreover, the association between T16189C and the poly-C
tract and CAD was very similar in both study centers, Salzburg
and Graz (Table 3).
Because a recent publication of our laboratory reported
mitochondrial haplogroup T to be significantly overrepresented
in CAD [29], we evaluated a possible association between
haplogroup T and T16189C as well as the poly-C tract. There
was linkage between haplogroup T and T16189C, but not
between the haplogroup and the poly-C tract. However, this
linkage was only partial, as the Pearson correlation coefficient was
low (r
2 (T16189C): 0.166). However, the association between
T16189C and the poly-C tract and CAD was independent of
mitochondrial haplogroup T. Evidence, that the frequency of
T16189C was independent of haplogroup T is that T16189C and
the poly-C tract were also significantly associated with CAD in
non-haplogroup T individuals (Table 4).
In the case of T2DM however, both T16189C and the poly-C
tract lost their significant association with the disease after
correction for age, sex and BMI (T16189C: p=0.08; poly-C
tract: p=0.13) (Table 2). After stratification of the disease
populations according to the study center, the association of
T16189C with T2DM remained significant after correction with
age, sex and BMI when the control population was compared to
patients from Graz (p,0.01) (Table 5), but not when the control
population was compared to patients from Salzburg (p=0.23)
(Table 5).
We also compared the frequencies of other polymorphisms of
the mtDNA CR (besides T16189C) between the control and
disease populations. Polymorphisms with a p-value lower than
0.05 were examined for associations with T16189C and
haplogroup T. When T2DM patients were compared to controls,
A16183C and T16224C were found to be significantly associated
with the disease; however, both also showed significant associa-
tions with T16189C. When CAD patients were compared to
controls, T16183C, C16294T, T16304C, A73G and T195C were
significantly associated with the disease. However, T16183C,
C16294T, A73G and T195C also showed associations with
T16189C, and T16304C is linked to mitochondrial haplogroup T
(subhaplogroup T2) (Supplementary Table S1 and S2) [29].
The mitochondrial haplogroup frequencies in the controls, the
CAD patients, and the T2DM patients are shown in Table 6. As
reported previously, mitochondrial haplogroup T is more frequent
in CAD whereas haplogroup H is underrepresented [29]. In the
case of patients with T2DM, no significant differences were
Table 3. Frequencies (%) of the CR polymorphism T16189C and the poly-C tract in patients with coronary artery disease from Graz
and Salzburg and controls as well as the corresponding Odds Ratios and 95% Confidence Intervals.
Controls
CAD
a
Graz
P-Valueb
(Pearson chi-
square test)
ORc
(95% CId)
aORe
(95% CId)
CAD
a
Salzburg
P-Valueb
(Pearson chi-
square test)
ORc
(95% CId)
aOR
e
(95% CI
d)
n=1481 n=191 n=291
T16189C 11.8 22.0 ,0.0001 2.10 (1.4–3.1) 2.17(1.4–3.3)*** 21.3 ,0.00005 2.02 (1.5–2.8) 2.08 (1.1–3.9)*
Poly-C tract 9.1 14.7 ,0.05 1.71 (1.1–2.7) 1.58 (1.0–2.5) 16.5 ,0.0005 1.97 (1.4–2.8) 1.58 (0.8–3.2)
aCAD = coronary artery disease.
bP-value: compared to controls.
cOR = Odds Ratio.
dCI = Confidence Interval.
eadjusted for age, sex and body mass index.
*p,0.05, p.0.01.
***p,0.001.
doi:10.1371/journal.pone.0016455.t003
Table 4. Frequencies (%) of the CR polymorphism T16189C and the poly-C tract in cases and controls with mitochondrial
haplogroups other than T as well as the corresponding Odds Ratios and 95% Confidence Intervals.
Subjects with
haplogroups
other than T Controls CAD
a
P-Valuec
(Pearson chi-
square test)
ORd
(95% CIe)
aORf
(95% CIe) T2DM
b
P-Valuec
(Pearson chi-
square test)
ORd
(95% CIe)
aORf
(95% CIe)
n=1355 n=411 n=455
T16189C 10.5 19.0 ,0.00001 2.00 (1.5–2.7) 1.95 (1.3–3.0)** 16.5 ,0.001 1.69 (1.2–2.3) 1.38 (0.8–2.3)
Poly-C tract 8.7 17.0 ,0.000005 2.15 (1.6–3.0) 2.03 (1.3–3.2)** 15.2 ,0.0001 1.87 (1.4–2.6) 1.46 (0.9–2.4)
aCAD = coronary artery disease.
bT2DM = type 2 diabetes mellitus.
cP-value: compared to controls.
dOR = Odds Ratio.
eCI = Confidence Interval.
fadjusted for age, sex and body mass index.
**p,0.01, p.0.001.
doi:10.1371/journal.pone.0016455.t004
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of the control population.
Discussion
In Asia, where the incidence of diabetes is growing rapidly
under the influence of a Western lifestyle, several studies have
reported that the 16189 variant is associated with multifactorial
diseases such as diabetes (and its risk factors), metabolic syndrome,
left ventricular hypertrophy and lacunar cerebral infarction [4–
6,8,9,12,13,21]. In Europe, however, the published data are
conflicting [3,11,14–20,22,23]. A reason for this discrepancy
might be that the prevalence of the T16189C polymorphism is
higher in Asia than in Middle Europe, and that the power of a
polymorphism to influence disease outcome is dependent on its
frequency in the population [30].
Indeed, in the present study we were able to find an elevated
frequency of T16189C and the poly-C tract in patients with
T2DM compared to controls. This association has to be viewed
with caution however, as the significant association was lost after
correction for age, sex and BMI. When the two study centers Graz
and Salzburg were analyzed independently, the association of
T2DM and T16189C was found to be significant in Graz, but not
in Salzburg, after applying adjustment for age, sex and BMI.
However, as the control subjects were recruited at the University
Hospital Salzburg, also the significant association of T16189C
with T2DM in Graz is questionable. Age was the most prominent
factor in reducing significance after correction. We don’t know
what other hidden confounders might have contributed to the
changed outcome of the model, however.
In contrast, in the present study we were able to show a
significant association of T16189C and the poly-C tract in the CR
of the mitochondrial genome with CAD in a Middle European
population for the first time. This association is independent of
mitochondrial haplogroup T and stable, also after correction for
age, sex and BMI and when analyzing the two study centers
separately. The associations of the poly-C tract and CAD are less
pronounced, but this seems to be only the result of a smaller
sample size, as the Odds Ratios are stable as well.
Recently, Abu-Amero et al detected a significantly higher
prevalence of T16189C (p=0.017, OR 1.524 (1.1–2.2)) and the
poly-C tract (p=0.041) in CAD patients (T16189C: 27.8%)
compared to controls (T16189C: 20.2%) in Saudi Arabs. In their
study, 669 patients with angiographically documented CAD
were compared to 258 control subjects. They reported that the
association of T16189C with CAD was influenced by age and
the presence of myocardial infarction [10]. Indeed, we also
found age to be a primary determinant in the reduction or loss of
significance in the association between this CR polymorphism
and CAD or T2DM in multiple regression analysis (Table 2, 3, 4
and 5). To exclude an influence of age on the observed
association, age stratification of controls was performed and
revealed again a significant association of CAD with T16189C.
Furthermore, an independent control group (n=200) recruited
at the Department of Ophthalmology (Paracelsus Medical
University, Salzburg, Austria), with an average age of 75 years,
shows nearly identical frequencies of T16189C and the poly-C
tract as the control group used in this study (data not shown),
indicating that age does not influence the frequency of these
variants.
Limitations of the present study are that the case and control
groups were not age- and sex-matched, and that the disease groups
from Salzburg and Graz were compared to the same control group
from Salzburg. However, our sample sizes were large (T2DM
n=505, CAD n=482, controls n=1481), the two study centers
are less than 200 miles apart and only included individuals of
Table 5. Frequencies (%) of the CR polymorphism T16189C and the poly-C tract in patients with type 2 diabetes from Graz and
Salzburg and controls as well as the corresponding Odds Ratios and 95% Confidence Intervals.
Controls
T2DM
a
Graz
P-Valueb
(Pearson chi-
square test)
ORc
(95% CId)
aORe
(95% CId)
T2DM
a
Salzburg
P-Valueb
(Pearson chi-
square test)
ORc
(95% CId)
aORe
(95% CId)
n=1481 n=226 n=279
T16189C 11.8 20.8 ,0.0005 1.96 (1.4–2.8) 3.45 (1.4–8.3)** 18.3 ,0.005 1.67 (1.2–2.4) 1.33 (0.8–2.1)
Poly-C tract 9.1 15.0 ,0.01 1.77 (1.2–2.6) 2.05 (0.7–5.6) 15.8 ,0.001 1.87 (1.3–2.7) 1.43 (0.9–2.4)
aT2DM = type 2 diabetes mellitus.
bP-value: compared to controls.
cOR = Odds Ratio.
dCI = Confidence Interval.
eadjusted for age, sex and body mass index.
**p,0.01, p.0.001.
doi:10.1371/journal.pone.0016455.t005
Table 6. Frequencies (%) of mitochondrial haplogroups in
cases and controls.
Haplogroup Controls
d CAD
ad T2DM
b
n=1481 n=482 n=505
H 43.7 37.3 42.6
U 15.5 15.4 14.6
J 11.5 11.0 9.3
T 8.5 14.7 9.9
K 5.3 2.9 4.3
W 2.1 1.9 1.6
V 1.7 3.1 3.2
I 0.9 1.3 1.8
X 1.3 3.1 3.0
Others
c 9.5 9.3 9.7
aCAD = coronary artery disease.
bT2DM = type 2 diabetes mellitus.
cHaplogroups that could not be assigned to one of the nine major European
haplogroups by the SNP combination.
dData on haplogroups have been reported recently [29].
doi:10.1371/journal.pone.0016455.t006
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are significant differences in the frequency of mtDNA variations in
healthy individuals between the two study centers.
In the literature, associations of the 16189 variant in the CR of
mtDNA with diseases have been hypothesized to result from
altered protein binding in this region, subsequently leading to
changed mtDNA replication [3]. Recently, Park et al observed that
the mitochondrial single-strand DNA-binding protein (mtSSB)
bound less efficiently to mtDNA having the 16189 variant
compared to mtDNA with the wild type sequence. This protein
functions in stabilising the D-loop and in maintaining mtDNA. A
novel origin of replication was found close to 16189 in the
mitochondrial CR, suggesting a model in which the 16189 variant
could reduce mitochondrial replication and thereby mtDNA
content of the cell through altered binding affinity of mtSSB [6].
Moreover, heteroplasmic cybrid cell lines generated by fusion of
mtDNA-free 143B cells with platelets from a patient who was
heteroplasmic for the 16189 variant quickly lost the mutant
mtDNA in culture. This indicates a reduced mtDNA replication
rate in cells with the 16189 variant [31].
Reduced mtDNA content could also affect the efficiency of the
electron transportchain,lowerthe ATP:ADPratio,and enhancethe
formation of ROS. An increase in ROS would cause mitochondrial
damage and further dysfunction of the electron transport chain,
initiating a vicious circle [32]. These two features, lower ATP:ADP
ratio and increased ROS production, could contribute to the onset
of the multifactorial diseases diabetes and CAD.
Moreover, Lin et al suggested that, in a diabetic state, patients
carrying the 16189 variant might not be able to cope in the same
way with oxidative damage as patients without the variant [33]. A
similar mechanism might be operative in patients with CAD.
Taken together, we propose a role for T16189C and the poly-C
tract in the complex aetiology of CAD in Austria. The role of
T16189C in T2DM remains unclear.
In CR polymorphisms other than T16189C and in haplogroups
other than T, no novel significant differences were found between
controls and patients with T2DM or CAD (a significantly higher
haplogroup T in CAD was published elsewhere [29]). Two recent
large studies also were not able to detect an influence of
mitochondrial haplogroups and polymorphisms in the develop-
ment of diabetes [34,35]. On the other hand, T2DM was found to
be associated with mitochondrial haplogroups J and T and with
polymorphisms T4216C and A4917G (in linkage with J and T), in
Caucasian-Brazilian patients [36].
As inter-study results for the same mitochondrial polymor-
phisms or haplogroups differ, it has to be kept in mind that the
diseases analysed are multifactorial. Associations with nuclear
polymorphisms and/or environmental factors not accounted for in
the study design could bias the outcome of the analysis. Regional
variation of polymorphism frequencies interacting with regional
variation of lifestyle habits such as diet and exercise could make
such contrasting findings possible.
Taken together, our findings reported here support previous
observations that T16189C has detrimental effects on mitochon-
drial function in CAD and possibly also in T2DM.
Methods
Ethics Statement
The study was conducted according to the Austrian Gene
Technology Act and complied with the Declaration of Helsinki.
All subjects gave written informed consent before entering the
study. The SAPHIR program was approved by the Local Province
of Salzburg Ethics Committee (‘‘Ethikkommission fu ¨r das Bundes-
land Salzburg; Amt der Salzburger Landesregierung, Abteilung 9
Gesundheit und Sport’’).
Study subjects
Data from 2468 Caucasian subjects from central (University
Hospital Salzburg) and southern (University Hospital Graz) Austria
were analysed. Patients with CAD were recruited at the University
Hospitals Salzburg (n=291) and Graz (n=191). All CAD patients
had angiographically documented CAD with at least one of the
main coronary arteries showing $50% stenosis. Patients with
T2DM were recruited from the diabetes outpatient clinics of the
University Hospital Salzburg and the Salzburg county Hospital
Hallein (n=279), and from the University Hospital Graz (n=226).
The control population consisted of 1481 unrelated individuals,
as previously described in detail [37]. Briefly, the cohort comprised
953 men between 39 and 66 years of age and 528 women between
39 and 67 years who were recruited to the Salzburg Atheroscle-
rosis Prevention Program (SAPHIR) [37]. Exclusion criteria for
participation in this study were a history of CAD, heart failure,
cerebrovascular disease, peripheral vascular disease, haemody-
namically relevant heart valve disease, chronic disease (of the liver
or kidney, autoimmune disorders, malignant cancer, haematologic
disorders, endocrinopathies, diabetes mellitus) and morbid obesity.
Laboratory methods have been described previously [37].
Mitochondrial DNA analysis
Mitochondrial haplogroups were assessed as described in our
recent studies [38,39]. Haplogroups that could not be assigned to
one of the nine major European haplogroups by their single
nucleotide polymorphism (SNP) combination were designated as
‘‘others’’. The haplogroup frequency in 1527 individuals of the
control cohort, in 487 subjects of the CAD group, and in 227
patients with T2DM from Graz were reported previously [29].
CR sequences were analysed between nucleotide positions
16147 and 500, as described previously [38]. In patients with
T2DM from Salzburg (n=279), only the T16189C polymorphism
and the poly-C tract were analysed.
Statistical analysis
Frequencies of all CR polymorphisms and of mitochondrial
haplogroups were tested for independence for disease state by
using Pearson chi-square statistics and Fisher’s exact test as
appropriate. Only haplogroups and polymorphisms with a
frequency higher than 5% were subjected to further statistical
analysis. A p-value ,0.05 was considered statistically significant.
Association of T16189C and the poly-C tract with T2DM and
CAD was corrected for age, sex and body mass index (BMI) by
logistic regression analysis. All analyses were performed using
SPSS 16.0 (SPSS GmbH, Germany).
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